ArticleiScience2026
MYZAP promotes angiogenesis by targeting RND1 after myocardial infarction.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) remains the leading cause of death due to cardiovascular disease worldwide. role of MYZAP in angiogenesis remains unclear. The expression of MYZAP in MI was significantly decreased. Endothelial-specific overexpression of MYZAP improved cardiac function, increased angiogenesis, and restored hindlimb blood flow levels in MI mice detected by MoorFLPIReview. The proliferation ability, migration, and invasion of endothelial cells were reduced after hypoxia, which were restored after overexpression of MYZAP or knockdown of RND1. The pro-angiogenic effect of MYZAP overexpression was reversed by RND1 overexpression. The proliferation ability, migration and invasion ability, and tube formation ability of endothelial cells were significantly reduced after knockdown of MYZAP. Direct interaction between MYZAP and RND1 was confirmed by co-immunoprecipitation (Co-IP) and thermal stability assays. TRIM21 was identified as a potential E3 ubiquitin ligase responsible for RND1 degradation. Our work revealed that endothelial-specific overexpression of MYZAP enhances angiogenesis by activating the VEGF/PI3K/AKT pathway in MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.